Clinical Features, Management, and Therapy of Plasma Cell Neoplasms: What Pathologists Need to Know

  • Giampaolo Talamo
  • Cerisse Harcourt
  • Maurizio Zangari
Chapter
First Online:

Abstract

Plasma cell neoplasms are characterized by the proliferation of monoclonal plasma cells and include a spectrum of disorders with different clinical manifestations. Multiple myeloma (MM) is the second most common hematological malignancy and recent studies have indicated that almost all cases of MM are preceded by a precursor state of monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). The main clinical manifestations of MM are summarized by the CRAB symptoms: hypercalcemia, renal insufficiency, anemia, and bone lesions. Survival of multiple myeloma patients has significantly improved in the last two decades. The clinical benefit has occurred mainly in the younger population with the introduction of high-dose chemotherapy and autologous stem cell transplantation (ASCT) and with the use of novel agents at the time of relapse. The use of novel agents in the elderly population has also resulted in a significant benefit with respect to outcome. Despite the use of these new agents, and the improvement of the median survival from 3 to 6 years in the last 20 years, MM is generally considered an incurable disease and relapse occurs in virtually all patients. Cytogenetic analysis and molecular biology studies indicate that MM is a heterogeneous disease. The non-satisfactory cure rate has been conditioned by intraclonal heterogeneity with branching evolutionary patterns.

Keywords

Multiple myeloma Smoldering myeloma Clinical manifestations CRAB symptoms Treatment 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998;30:493–501.CrossRefPubMedGoogle Scholar
  3. 3.
    Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet 2014.Google Scholar
  4. 4.
    Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418–22.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Mangiacavalli S, Cocito F, Pochintesta L, et al. Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol. 2013;91:356–60.PubMedGoogle Scholar
  11. 11.
    Rago A, Grammatico S, Za T, et al. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. Cancer. 2012;118:5544–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMedGoogle Scholar
  14. 14.
    Kakkar N, Das S. Relapse of multiple myeloma: diagnosis by clot section alone with negative bone marrow aspirate and trephine biopsy. Indian J Pathol Microbiol. 2009;52:290–1.CrossRefPubMedGoogle Scholar
  15. 15.
    Ceneli O, Haznedar R. Advanced multiple myeloma with negative bone marrow biopsy and positive soft tissue lesions in the (18)F-FDG PET/CT scan. Hell J Nucl Med. 2008;11:56–7.PubMedGoogle Scholar
  16. 16.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.CrossRefPubMedGoogle Scholar
  17. 17.
    Start DA, Silva FG, Davis LD, et al. Myeloma cast nephropathy: immunohistochemical and lectin studies. Mod Pathol. 1988;1:336–47.PubMedGoogle Scholar
  18. 18.
    Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;158:1859–66.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Maldonado JE, Velosa JA, Kyle RA, et al. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med. 1975;58:354–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Papanikolaou X, Repousis P, Tzenou T, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54:1459–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Talamo G, Dolloff NG, Sharma K, et al. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. Rare Tumors. 2012;4:e39.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011;22:1628–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Pozzi C, D’Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154–63.CrossRefPubMedGoogle Scholar
  26. 26.
    Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:591–601.CrossRefPubMedGoogle Scholar
  27. 27.
    Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Katzmann JA, Clark R, Wiegert E, et al. Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. Electrophoresis. 1997;18:1775–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Bienvenu J, Graziani MS, Arpin F, et al. Multicenter evaluation of the Paragon CZE 2000 capillary zone electrophoresis system for serum protein electrophoresis and monoclonal component typing. Clin Chem. 1998;44:599–605.PubMedGoogle Scholar
  30. 30.
    Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215–24.CrossRefPubMedGoogle Scholar
  31. 31.
    Wozney JL, Damluji AA, Ahmed F, et al. Estimation of daily proteinuria in patients with multiple myeloma by using the protein-to-creatinine ratio in random urine samples. Acta Haematol. 2010;123:226–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517–22.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRefPubMedGoogle Scholar
  34. 34.
    San Miguel JF, Sanchez J, Gonzalez M. Prognostic factors and classification in multiple myeloma. Br J Cancer. 1989;59:113–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bartl R, Frisch B, Fateh-Moghadam A, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:342–55.CrossRefPubMedGoogle Scholar
  36. 36.
    Seegmiller AC, Xu Y, McKenna RW, et al. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol. 2007;127:176–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29:1627–33.CrossRefPubMedGoogle Scholar
  38. 38.
    Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095–100.CrossRefPubMedGoogle Scholar
  39. 39.
    Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23:1545–56.CrossRefPubMedGoogle Scholar
  40. 40.
    Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657–64.CrossRefPubMedGoogle Scholar
  41. 41.
    Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.CrossRefPubMedGoogle Scholar
  42. 42.
    Nanni C, Zamagni E, Celli M, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38:e74–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Abildgaard N, Brixen K, Kristensen JE, et al. Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol. 1996;57:370–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191–200.CrossRefPubMedGoogle Scholar
  45. 45.
    Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117:4468–74.CrossRefPubMedGoogle Scholar
  47. 47.
    Gerry D, Lentsch EJ. Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg. 2013;148:974–81.CrossRefPubMedGoogle Scholar
  48. 48.
    Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438–47.CrossRefPubMedGoogle Scholar
  49. 49.
    Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–6.PubMedGoogle Scholar
  50. 50.
    Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer. 2012;118:1585–92.CrossRefPubMedGoogle Scholar
  51. 51.
    Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867–74.CrossRefPubMedGoogle Scholar
  52. 52.
    Kumar S, Lacy MQ, Dispenzieri A, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004;34:485–90.CrossRefPubMedGoogle Scholar
  53. 53.
    Jagannath S, Kyle RA, Palumbo A, et al. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk. 2010;10:28–43.CrossRefPubMedGoogle Scholar
  54. 54.
    Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–77.CrossRefPubMedGoogle Scholar
  58. 58.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71.CrossRefPubMedGoogle Scholar
  59. 59.
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.CrossRefPubMedGoogle Scholar
  60. 60.
    Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934–9.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–16.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.CrossRefPubMedGoogle Scholar
  63. 63.
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.CrossRefPubMedGoogle Scholar
  64. 64.
    O’Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15:7085–91.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12:310–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.CrossRefPubMedGoogle Scholar
  68. 68.
    Shah N, Callander N, Ganguly S, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015.Google Scholar
  69. 69.
    Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Talamo G, Dimaio C, Abbi KK, et al. Current role of radiation therapy for multiple myeloma. Front Oncol. 2015;5:40.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31:2347–57.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989–99.CrossRefPubMedGoogle Scholar
  73. 73.
    Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12:225–35.CrossRefPubMedGoogle Scholar
  74. 74.
    Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist. 2007;12:664–89.CrossRefPubMedGoogle Scholar
  75. 75.
    Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMedGoogle Scholar
  76. 76.
    Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–95.CrossRefPubMedGoogle Scholar
  77. 77.
    Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117:2009–11.CrossRefPubMedGoogle Scholar
  78. 78.
    Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313–25.CrossRefPubMedGoogle Scholar
  79. 79.
    Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546–58.CrossRefPubMedGoogle Scholar
  80. 80.
    Pawlyn C, Melchor L, Murison A, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015;125:831–40.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–75.CrossRefPubMedGoogle Scholar
  82. 82.
    Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008;26:4798–805.CrossRefPubMedGoogle Scholar
  83. 83.
    Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–84.CrossRefPubMedGoogle Scholar
  84. 84.
    Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26:2406–13.CrossRefPubMedGoogle Scholar
  85. 85.
    Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12–8.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881–7.CrossRefPubMedGoogle Scholar
  87. 87.
    Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–95.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Bachar G, Goldstein D, Brown D, et al. Solitary extramedullary plasmacytoma of the head and neck–long-term outcome analysis of 68 cases. Head Neck. 2008;30:1012–9.CrossRefPubMedGoogle Scholar
  90. 90.
    Talamo G, Farooq U, Zangari M, et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010;10:464–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Giampaolo Talamo
    • 1
  • Cerisse Harcourt
    • 2
  • Maurizio Zangari
    • 2
  1. 1.Penn State Hershey Cancer InstituteHersheyUSA
  2. 2.Myeloma Institute for Research and TherapyUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations